1. Home
  2. COLL vs AOD Comparison

COLL vs AOD Comparison

Compare COLL & AOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • AOD
  • Stock Information
  • Founded
  • COLL 2002
  • AOD 2006
  • Country
  • COLL United States
  • AOD United Kingdom
  • Employees
  • COLL N/A
  • AOD N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • AOD Investment Managers
  • Sector
  • COLL Health Care
  • AOD Finance
  • Exchange
  • COLL Nasdaq
  • AOD Nasdaq
  • Market Cap
  • COLL 864.7M
  • AOD 862.4M
  • IPO Year
  • COLL 2015
  • AOD N/A
  • Fundamental
  • Price
  • COLL $30.23
  • AOD $8.57
  • Analyst Decision
  • COLL Strong Buy
  • AOD
  • Analyst Count
  • COLL 5
  • AOD 0
  • Target Price
  • COLL $43.80
  • AOD N/A
  • AVG Volume (30 Days)
  • COLL 321.1K
  • AOD 452.9K
  • Earning Date
  • COLL 05-08-2025
  • AOD 01-01-0001
  • Dividend Yield
  • COLL N/A
  • AOD 12.76%
  • EPS Growth
  • COLL N/A
  • AOD 213.63
  • EPS
  • COLL 1.25
  • AOD 1.93
  • Revenue
  • COLL $664,283,000.00
  • AOD $72,962,082.00
  • Revenue This Year
  • COLL $20.00
  • AOD N/A
  • Revenue Next Year
  • COLL $3.74
  • AOD N/A
  • P/E Ratio
  • COLL $24.13
  • AOD $4.38
  • Revenue Growth
  • COLL 17.17
  • AOD N/A
  • 52 Week Low
  • COLL $23.23
  • AOD $6.99
  • 52 Week High
  • COLL $42.29
  • AOD $9.14
  • Technical
  • Relative Strength Index (RSI)
  • COLL 64.41
  • AOD 62.73
  • Support Level
  • COLL $28.81
  • AOD $8.41
  • Resistance Level
  • COLL $30.17
  • AOD $8.55
  • Average True Range (ATR)
  • COLL 1.02
  • AOD 0.08
  • MACD
  • COLL 0.37
  • AOD 0.04
  • Stochastic Oscillator
  • COLL 93.13
  • AOD 99.57

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest

Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.

Share on Social Networks: